RE:Proph what happened"AEZS is still every much a mystery until we see a plan, data, and key events."
I've always said that we are ahead of the key defining events. That's what makes it interesting. You are the guy that likes to buy after the events when a fund manager talks his book on BNN and you are left holding the bag. We are early here.
The defining events are the diagnostic data, approval and licensing deal. PGX to Health Canada approval this year and to the decision point for mass industrialization(100L scale-up) as well as licensing deal validating the technology. We haven't even seen preclinical data for the avenanthramide pill and now we are before human safety/tolerability and preliminary efficacy data. We don't have a regulatory path forward for AEZS's pipeline assets and key data is coming from Harvard in their NMOSD models that have been used for other NMOSD assets. PGX-YBG/fibrosis data has been sent to the peer-review journal Biomaterials and should be published shortly. Gilles said that a short toxicology study was needed before Phase I human trials. The final data from the Angiogenesis Foundation should be near setting it up for potential licensing.
We also need to see a plan for which assets are the priority and the cash runway to material events. Hopefully this comes at the AGM.
With Gilles on the inside of AEZS he is in the catbird seat in terms of understandng the deals AEZS has been working on as well as the assets. Ronnie Miller is "thrilled" and has now called assets "transformational". Ronnie has been trained in excellence at the world's largest biotech. This is consistent with the data so far.
Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”
After a decade of work now is the time for NASDAQ and the merger has been closed. Gilles says he's "excited". Ronnie is "thrilled". HC Wainwright had a C$100 million market cap target price for AEZS before the merger and the previous licensing deal was for C$40 million upfront cash on an inflation-adjusted basis. This was a merger of equals suggesting a potential C$200 million market cap target valuation.
Now we wait for the key defining events... They are closer than ever!